Evidence map›Paper›PMID 36507719›Full record

ArticleDeutsches Arzteblatt international2023

Potentially Inadequate Medications in the Elderly: PRISCUS 2.0.

Nina-Kristin Mann, Tim Mathes, Andreas Sönnichsen, Dawid Pieper, Elisabeth Klager, Mahmoud Moussa, Petra A Thürmann

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Deutsches Arzteblatt international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. [Specialized geriatric care in intensive care units: from frailty to functional prognosis].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026
    Review
  17. Article
  18. Article
  19. [Why represcribing instead of deprescribing?]Innere Medizin (Heidelberg, Germany) · 2026
    Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nina-Kristin MannChair of Clinical Pharmacology, Department of Medicine, Faculty of Health, University of Witten/Herdecke; Institute of Medical Statistics, Faculty of Medicine, University of Göttingen; Institute of Knowledge Management in Medicine, Salzburg, Austria; Institute for Research in Operative Medicine, Department of Medicine, Faculty of Health, University of Witten/Herdecke; Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Austria; Department of General and Family Medicine, Center for Public Health, Medical University of Vienna, Austria; Philipp Klee Institute of Clinical Pharmacology, Helios University Hospital, Wuppertal.
Tim Mathes
Andreas Sönnichsen
Dawid Pieper
Elisabeth Klager
Mahmoud Moussa
Petra A Thürmann
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe term potentially inadequate medication (PIM) is used to describe substances that may be unsuitable for use inthe elderly and should be avoided. The PRISCUS list, published in 2010, was the first catalog of PIM designed for the Germandrug market to become adopted in practice. While 24% of German patients aged ≥ 65 years were prescribed at least one PIMper year in 2009, the proportion in 2019 was only 14.5%.

methodsIn a three-round Delphi process, experts from clinical practice and research evaluated whether selected substancesare PIM for the elderly. The participants were provided with dedicated literature including systematic reviews carried out for theparticular purposes of this project.

resultsFifty-nine persons took part in the Delphi process and, in addition, contributed comments and therapeutic alternatives.Altogether, 187 substances were classed as PIM. One hundred thirty-three of the substances now listed were not in the originalPRISCUS list: these include some oral antidiabetics, all of the selective COX-2 inhibitors, and moderately long acting benzodiazepinessuch as oxazepam. For some other substances, e.g., proton pump inhibitors (PPI), the advisability of treatment formore than 8 weeks was considered as potentially inappropriate, as was the use of ibuprofen in doses >1200 mg/day and formore than 1 week without PPI. Risperidone for more than 6 weeks is also PIM.

conclusionThe new, greatly extended PRISCUS list must now be validated in epidemiological and prospective studies and itspracticability in routine daily use must be verified.

Indexed as

Hypoglycemic AgentsIbuprofenAgedHumansProspective StudiesProton Pump InhibitorsHypoglycemic AgentsIbuprofenProton Pump Inhibitors

Identifiers

PMID36507719
PMCPMC10035347
OpenAlexW4311287682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.